Method for the treatment of multiple sclerosis
A method for treating a subject with multiple sclerosis is disclosed herein. In one embodiment, a method is provided for treating a subject with multiple sclerosis that includes administering to the subject a therapeutically effective amount of an IL-21 receptor antagonist, wherein the subject has failed to respond treatment with beta interferon, thereby treating the subject.
1. A method of treating a human subject suffering from relapsing remitting multiple sclerosis, comprising administering daclizumab monthly to the subject in a unit dose ranging from about 150 mg to about 400 mg, wherein the subject is not concurrently treated with interferon-β.
2. The method of claim 1 , wherein the daclizumab is administered for a year.
3. The method of claim 1 , wherein the daclizumab is administered indefinitely.
4. The method of claim 1 , wherein the daclizumab is formulated as a solution containing from 1 wt % to 15 wt % or 20 wt % daclizumab.
5. The method of claim 1 , wherein the daclizumab is administered is administered as monotherapy.
6. The method of claim 1 , wherein the daclizumab is administered in an amount effective to reduce the rate of increase of the subject's disability score.
7. A method of treating a human subject suffering from relapsing remitting multiple sclerosis, comprising administering monthly to the subject a humanized monoclonal antibody that specifically binds the alpha subunit of the interleukin-2 receptor in a dose ranging from about 150 mg to about 400 mg, wherein the subject is not concurrently treated with interferon-β, and wherein the antibody comprises:
(a) a V H chain having the amino acid sequence:
QVQLVQSGAE VKKPGSSVKV SCKASGYTFT SYRMHWVRQ APGQGLEWIG YINPSTGYTEY NQKFKDKATI TADESTNTAY MELSSLRSED TAVYYCARGG GVFDYWGQG TLVTVSS (SEQ ID NO: 1); and
(b) a V L chain having the amino acid sequence:
DIQMTQSPS TLSASVGDR VTITCSASSS ISYMHWYQ QKPGKAPK LLIYTTSNLAS GVPARFSG SGSGTEFTLT ISSLQPDDF ATYYCHQRS TYPLTFGQG TKVEVK (SEQ ID NO: 2).
8. The method of claim 7 , wherein the humanized monoclonal antibody is administered for a year.
9. The method of claim 7 , wherein the humanized monoclonal antibody is administered indefinitely.
10. The method of claim 7 , wherein the humanized monoclonal antibody is formulated as a solution containing from 1 wt % to 15 wt % or 20 wt % antibody.
11. The method of claim 7 , wherein the humanized monoclonal antibody is administered in a unit dosage form containing 150 mg antibody.
12. The method of claim 7 , wherein the humanized monoclonal antibody is administered in a unit dosage form containing 200 mg antibody.
13. The method of claim 7 , wherein the humanized monoclonal antibody is administered as monotherapy.
14. The method of claim 7 , wherein the humanized monoclonal antibody is administered in an amount effective to decrease the number of contrast enhancing-lesions in the subject as evaluated by Magnetic Resonance Imaging.
15. The method of claim 7 , wherein the humanized monoclonal antibody is administered in an amount effective to reduce the rate of increase of the subject's disability score.